- Clinical Evidence Along With Featured Products Highlight Biennial Meeting of Cardiologists
—
MINNEAPOLIS, Minnesota and NICE, France, June 16MINNEAPOLIS, Minnesota and NICE, France, June 16 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT) today announced its schedule of activities for Cardiostim 2008 - 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques, being held 18-21 June 2008. Media and physician attendees are invited to the following:
- A symposium on REVERSE (Resynchronisation Reverses Remodeling in Systolic Left Ventricular Dysfunction), including the first look at 18-month European data, will be held from 14.00-15.30 Wednesday, 18 June, in Room Athena at the Acropolis Convention Centre. REVERSE is the first large-scale, global, randomised, double-blind trial to evaluate cardiac resynchronisation therapy (CRT) in asymptomatic or mildly symptomatic heart failure patients (NYHA Class I, II).
- ADVANCE CRT-D (ATP Delivery for Painless ICD Therapy) is an international, prospective, randomized, controlled, single blind trial to compare the safety and efficacy of anti-tachycardia pacing simultaneously delivered from the right and left ventricles (lower chambers of the heart, also known as Bi-ventricular delivery) vs. conventional right ventricular delivery. Data on ADVANCE CRT-D will be presented at 11.20 Thursday, 19 June, in Room Thalie 3.2.
- RELEVANT is a prospective, controlled, parallel, multicenter trial investigating the effectiveness and safety of simplified programming for biventricular defibrillators (CRT-D) in patients with non-ischemic heart failure and a primary prevention ICD indication. Data on RELEVANT will be presented at 11.00 Wednesday, June 18, in Room 1.4.
Further, Medtronic announces that enrollments in its Sense-HF (Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure) trial will be completed by the end of June 2008. Sense-HF is a prospective, observational, multicentre, event-driven, international study to evaluate the sensitivity and positive predictive value of Medtronic's proprietary OptiVol(R) Fluid Trend data in predicting heart failure-related hospitalisations and health care utilisations associated with the signs and symptoms of worsening heart failure.
Medtronic also is supporting the following Scientific Sessions:
Wednesday, 18 June
- Product Performance: Tracking, Transparency and Truth, from 14.00-15.30 in Room 1.4, chaired by Dr. M. Santini and Dr. E. Prystowsky
- CareLink: Prime Time for Need-Based Care, from 16.00-17.30 in Room Calliope 3.5, chaired by Dr. J. Morgan and Dr. P. Geelen
Thursday, 19 June
- The Future of Stimulation Therapy, from 9.00-10.30 in Room 1.2, chaired by Dr. A. Proclemer and Dr. L. Mont
- Innovative ICD Solutions for Primary Prevention Patients, from 11.00-12.30 in Room Thalie 3.2, chaired by Dr. D. Andresen and Dr. P. Mabo
- CRT Therapy: Getting the Best Outcome for Patients Through Optimization, from 16.00-17.30 in Room Iris 1.6, by Dr. M. Lunati and Dr. P. Delnoy
Friday, 20 June
- Evidence in CRT: Where Are We and Where Are We Going?, from 9.00-10.30 in Room Iris 1.6, chaired by Dr. P. Ritter and Dr. A. Buxton
- Implantable Cardiac Monitors: Symptoms Do Not Tell the Full Story, from 11.00-12.30 in Room Calliope 3.5, chaired by Dr. H. Heidbuchel and Dr. R. Sutton
All presentation times are local to Nice.
In addition to attending these data presentations and other educational and scientific sessions, Cardiostim attendees are encouraged to visit the Medtronic exhibit, composed of a Therapy area (B20), a Diagnostics and Monitoring area (A8), CareLink Lounge (B7), and Medtronic Academia Village (Gallieni 29), featuring the company's newest products, the Vision 3D(TM) portfolio of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds), which is making its European debut at Cardiostim after having received CE Mark in late spring 2008. The Medtronic Academia Village will offer the opportunity to meet leaders in medical technology education and training. It also includes state-of-the-art simulators for electrophysiology and device applications, as well as informative sessions from 10.30-16.00 Wednesday, 18 June - Friday, 20 June.
About Medtronic
Medtronic, Inc. http://www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 27, 2007. Actual results may differ materially from anticipated results.
Contacts: Yvan Deurbroeck Public Relations (Europe) +41-21-802-7574 Jeff Warren Investor Relations +1-763-505-2696 Tracy McNulty Public Relations (U.S.) +1-763-526-2492
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
